

## APPENDIX

## 5B

## Specimen Financial Statements: The Procter & Gamble Company

The following pages contain the financial statements, accompanying notes, and other information from the 2004 annual report of **The Procter & Gamble Company (P&G)**. The Procter & Gamble Company manufactures and markets a range of consumer products in various countries throughout the world. The Company markets over 300 branded products in more than 160 countries. It manages its business in five product segments: Fabric and Home Care, Baby and Family Care, Beauty Care, Health Care, and Snacks and Beverages.

We do not expect that you will comprehend P&G's financial statements and the accompanying notes in their entirety at your first reading. But we expect that by the time you complete the material in this textbook, your level of understanding and interpretive ability will have grown enormously.

At this point we recommend that you take 20 to 30 minutes to scan the following statements and notes. Your goal should be to familiarize yourself with the contents and accounting elements. Throughout the following 19 chapters, when you are asked to refer to specific parts of P&G's financial statements, do so! Then, when you have completed reading this book, we challenge you to reread P&G's financials to see how much greater and more sophisticated your understanding of them has become.

The P&G logo is displayed in a blue, italicized serif font.


Consumers around the world trust P&G brands – such as Pampers, Tide, Ariel, Pantene, Wella, Always, Crest, Bounty, Charmin, Olay, Pringles, Iams, Downy, Actonel, Folgers and Head & Shoulders – to make everyday life a little bit better. Almost 110,000 P&G people in over 80 countries worldwide work hard to earn that trust.

*Touching lives, improving life. P&G.*


### Financial Highlights

Amounts in millions except per share amounts	Years Ended June 30		
	2004	2003	% Change
Net Sales	\$51,407	\$43,377	19%
Operating Income	9,827	7,853	25%
Net Earnings	6,481	5,186	25%
Per Common Share <sup>1</sup>			
Diluted Net Earnings	2.32	1.85	25%
Dividends	0.93	0.82	13%


Net Sales  
(in billions of dollars)




Operating Cash Flow  
(in billions of dollars)



Diluted Net Earnings  
(per common share)



Additional Earnings Information  
(per common share, on a diluted basis)




● Reported EPS  
● Restructuring Charges

### Fellow Shareholders,


P&G is delivering broad-based, organic growth driven by clear strategies and a unique combination of P&G strengths. P&G's performance has accelerated over the past three years, and we are confident double-digit earnings-per-share growth is sustainable for the foreseeable future.




Organic Unit Volume Growth  
(% increase versus previous year)



Free Cash Flow  
(in billions of dollars)



Total Shareholder Return  
(indexed versus June 30, 2001)



## 204 • Specimen Financial Statements: The Procter &amp; Gamble Company


 Consistent  
Performance

Three years of strong performance is a good start, but it's long-term performance that counts. Consistent performance is not easy. Growing P&G sales 4%–6% per year is roughly the equivalent of adding a brand the size of Tide – every year.

We're confident P&G can reliably deliver the future growth to which we've committed. Our strategies are working. There still is room to grow. Our strengths enable us to respond to external trends and challenges. Major changes are improving the consistency of P&G performance.


 Sources of  
Confidence


 P&G's  
Growth  
Strategy


Build existing core businesses into strong global leaders.



Grow leading brands in big countries with winning customers. Accelerate growth in Western Europe.



Accelerate faster-growing, higher-margin health and beauty businesses.



Accelerate growth in developing markets and with lower-income consumers.


 Earning  
Your  
Trust

P&G strategies, strengths, and the systemic and structural changes we've made to improve the reliability of our performance should give shareholders confidence that P&G can sustain double-digit earnings-per-share growth for the foreseeable future.

A.G. Lafley  
Chairman of the Board,  
President and Chief Executive

August 6, 2004

## Management's Responsibility for Financial Reporting

Procter & Gamble has been built through the generations by the character of its people. That character is reflected in our Purpose, Values and Principles and in how well we live them as individuals and as a Company. High quality financial reporting is one of our responsibilities – one that we execute with integrity.

High quality financial reporting is characterized by accuracy, objectivity and transparency. Management is responsible for maintaining an effective system of internal controls over financial reporting to deliver those characteristics in all material respects. The Board of Directors, through its Audit Committee, provides oversight. They have engaged Deloitte & Touche LLP to audit our consolidated financial statements, on which they have issued an unqualified opinion.

Our commitment to providing timely, accurate and understandable information to investors encompasses:

**Communicating expectations to employees.** Key employee responsibilities are reinforced through the Company's "Worldwide Business Conduct Manual," which sets forth the Company's commitment to conduct its business affairs with high ethical standards. Every one of P&G's employees – from senior management on down – is held personally accountable for compliance. The Worldwide Business Conduct Manual is available on our website at [www.pg.com](http://www.pg.com).

**Maintaining a strong internal control environment.** Our system of internal controls includes written policies and procedures, segregation of duties and the careful selection and development of employees. The system is designed to provide reasonable assurance that transactions are executed as authorized and appropriately recorded, that assets are safeguarded and that accounting records are sufficiently reliable to permit the preparation of financial statements that conform in all material respects with accounting principles generally accepted in the United States of America. We monitor these internal controls through control self-assessments by business unit management and an ongoing program of internal audits around the world.

**Executing financial stewardship.** We maintain specific programs and activities to ensure that employees understand their fiduciary responsibilities to shareholders. This ongoing effort encompasses financial discipline in our strategic and daily business decisions and brings particular focus to maintaining accurate financial reporting and effective controls through process improvement, skill development and oversight.

**Exerting rigorous oversight of the business.** We continuously review our business results and strategic choices. Our Global Leadership Council is actively involved – from understanding strategies to reviewing key initiatives, financial performance and control assessments. The intent is to ensure we remain objective in our assessments, constructively challenge the approach to business opportunities, identify potential issues and ensure reward and recognition systems are appropriately aligned with results.

**Engaging our Disclosure Committee.** We maintain disclosure controls and procedures designed to ensure that information required to be disclosed is recorded, processed, summarized and reported timely and accurately. Our Disclosure Committee is a group of senior-level executives responsible for evaluating disclosure implications of significant business activities and events. The Committee reports its findings to the CEO and CFO, providing an effective process to evaluate our external disclosure obligations.

**Encouraging strong and effective corporate governance from our Board of Directors.** We have an active, capable and diligent Board that meets the required standards for independence, and we welcome the Board's oversight as a representative of the shareholders. Our Audit Committee comprises independent directors with the financial knowledge and experience to provide appropriate oversight. We review significant accounting policies, financial reporting and internal control matters with them and encourage their independent discussions with our external auditors. Our corporate governance guidelines, as well as the charter of the Audit Committee and certain other committees of our Board, are available on our website at [www.pg.com](http://www.pg.com).

P&G has a strong history of doing what's right. We know great companies are built on strong ethical standards and principles. Our financial results are delivered from that culture of accountability, and we take responsibility for the quality and accuracy of our financial reporting. We present this information proudly, with the expectation that those who use it will understand our Company, recognize our commitment to performance with integrity and share our confidence in P&G's future.



A. G. Lafley

Chairman of the Board,  
President and Chief Executive



Clayton C. Daley, Jr.

Chief Financial Officer

## 206 • Specimen Financial Statements: The Procter &amp; Gamble Company

Report of Independent Registered  
Public Accounting Firm

## Deloitte.

To the Board of Directors and Shareholders of  
The Procter & Gamble Company:

We have audited the accompanying consolidated balance sheets of The Procter & Gamble Company and subsidiaries (the "Company") as of June 30, 2004 and 2003 and the related consolidated statements of earnings, shareholders' equity and cash flows for each of the three years in the period ended June 30, 2004. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of the Company at June 30, 2004 and 2003 and the results of its operations and cash flows for each of the three years in the period ended June 30, 2004, in conformity with accounting principles generally accepted in the United States of America.

*Deloitte + Touche LLP*

Deloitte & Touche LLP  
Cincinnati, Ohio

August 6, 2004

## Consolidated Statements of Earnings

Amounts in millions except per share amounts	Years Ended June 30		
	2004	2003	2002
<b>Net Sales</b>	<b>\$51,407</b>	\$43,377	\$40,238
Cost of products sold	25,076	22,141	20,989
Selling, general and administrative expense	16,504	13,383	12,571
<b>Operating Income</b>	<b>9,827</b>	7,853	6,678
Interest expense	629	561	603
Other non-operating income, net	152	238	308
<b>Earnings Before Income Taxes</b>	<b>9,350</b>	7,530	6,383
Income taxes	2,869	2,344	2,031
<b>Net Earnings</b>	<b>\$6,481</b>	\$5,186	\$4,352
<b>Basic Net Earnings Per Common Share<sup>1</sup></b>	<b>\$2.46</b>	\$1.95	\$1.63
<b>Diluted Net Earnings Per Common Share<sup>1</sup></b>	<b>\$2.32</b>	\$1.85	\$1.54
<b>Dividends Per Common Share<sup>1</sup></b>	<b>\$0.93</b>	\$0.82	\$0.76

<sup>1</sup> Restated for two-for-one stock split effective May 21, 2004.

See accompanying Notes to Consolidated Financial Statements

## Specimen Financial Statements: The Procter &amp; Gamble Company • 207

## Consolidated Statements of Cash Flows

Amounts in millions	Years ended June 30		
	2004	2003	2002
<b>Cash and Cash Equivalents, Beginning of Year</b>	<b>\$5,912</b>	<b>\$3,427</b>	<b>\$2,306</b>
<b>Operating Activities</b>			
Net earnings	6,481	5,186	4,352
Depreciation and amortization	1,733	1,703	1,693
Deferred income taxes	415	63	389
Change in accounts receivable	(159)	163	96
Change in inventories	56	(56)	159
Change in accounts payable, accrued and other liabilities	625	936	684
Change in other operating assets and liabilities	(88)	178	(98)
Other	299	527	467
<b>Total Operating Activities</b>	<b>9,362</b>	<b>8,700</b>	<b>7,742</b>
<b>Investing Activities</b>			
Capital expenditures	(2,024)	(1,482)	(1,679)
Proceeds from asset sales	230	143	227
Acquisitions	(7,476)	(61)	(5,471)
Change in investment securities	(121)	(107)	88
<b>Total Investing Activities</b>	<b>(9,391)</b>	<b>(1,507)</b>	<b>(6,835)</b>
<b>Financing Activities</b>			
Dividends to shareholders	(2,539)	(2,246)	(2,095)
Change in short-term debt	4,911	(2,052)	1,394
Additions to long-term debt	1,963	1,230	1,690
Reductions of long-term debt	(1,188)	(1,060)	(461)
Proceeds from the exercise of stock options	555	269	237
Treasury purchases	(4,070)	(1,236)	(568)
<b>Total Financing Activities</b>	<b>(368)</b>	<b>(5,095)</b>	<b>197</b>
<b>Effect of Exchange Rate Changes on Cash and Cash Equivalents</b>	<b>(46)</b>	<b>387</b>	<b>17</b>
<b>Change in Cash and Cash Equivalents</b>	<b>(443)</b>	<b>2,485</b>	<b>1,121</b>
<b>Cash and Cash Equivalents, End of Year</b>	<b>\$5,469</b>	<b>\$5,912</b>	<b>\$3,427</b>
<b>Supplemental Disclosure</b>			
Cash payments for:			
Interest	\$630	\$538	\$629
Income taxes	1,634	1,703	941
Non-cash spin-off of Jif and Crisco businesses	-	-	150
<b>Acquisition of Businesses</b>			
Fair value of assets acquired, excluding cash	\$11,954	\$61	\$6,042
Fair value of liabilities assumed	(4,478)	-	(571)
<b>Acquisitions</b>	<b>7,476</b>	<b>61</b>	<b>5,471</b>

See accompanying Notes to Consolidated Financial Statements

## 208 • Specimen Financial Statements: The Procter &amp; Gamble Company

## Consolidated Balance Sheets

## Assets

Amounts in millions	June 30	
	2004	2003
<b>Current Assets</b>		
Cash and cash equivalents	\$5,469	\$5,912
Investment securities	423	300
Accounts receivable	4,062	3,038
Inventories		
Materials and supplies	1,191	1,095
Work in process	340	291
Finished goods	2,869	2,254
Total Inventories	4,400	3,640
Deferred income taxes	958	843
Prepaid expenses and other receivables	1,803	1,487
<b>Total Current Assets</b>	<b>17,115</b>	<b>15,220</b>
<b>Property, Plant and Equipment</b>		
Buildings	5,206	4,729
Machinery and equipment	19,456	18,222
Land	642	591
	25,304	23,542
Accumulated depreciation	(11,196)	(10,438)
<b>Net Property, Plant and Equipment</b>	<b>14,108</b>	<b>13,104</b>
<b>Goodwill and Other Intangible Assets</b>		
Goodwill	19,610	11,132
Trademarks and other intangible assets, net	4,290	2,375
<b>Net Goodwill and Other Intangible Assets</b>	<b>23,900</b>	<b>13,507</b>
<b>Other Non-Current Assets</b>	<b>1,925</b>	<b>1,875</b>
<b>Total Assets</b>	<b>\$57,048</b>	<b>\$43,706</b>

See accompanying Notes to Consolidated Financial Statements

## Specimen Financial Statements: The Procter &amp; Gamble Company • 209

**Consolidated Balance Sheets****Liabilities and Shareholders' Equity**

Amounts in millions	June 30	
	2004	2003
<b>Current Liabilities</b>		
Accounts payable	\$3,617	\$2,795
Accrued and other liabilities	7,689	5,512
Taxes payable	2,554	1,879
Debt due within one year	8,287	2,172
<b>Total Current Liabilities</b>	<b>22,147</b>	<b>12,358</b>
<b>Long-Term Debt</b>	<b>12,554</b>	<b>11,475</b>
<b>Deferred Income Taxes</b>	<b>2,261</b>	<b>1,396</b>
<b>Other Non-Current Liabilities</b>	<b>2,808</b>	<b>2,291</b>
<b>Total Liabilities</b>	<b>39,770</b>	<b>27,520</b>
<b>Shareholders' Equity<sup>1</sup></b>		
Convertible Class A preferred stock, stated value \$1 per share (600 shares authorized)	1,526	1,580
Non-Voting Class B preferred stock, stated value \$1 per share (200 shares authorized)	-	-
Common stock, stated value \$1 per share (5,000 shares authorized; shares outstanding: 2004 - 2,543.8, 2003 - 2,594.4)	2,544	2,594
Additional paid-in capital	2,425	1,634
Reserve for ESOP debt retirement	(1,283)	(1,308)
Accumulated other comprehensive income	(1,545)	(2,006)
Retained earnings	13,611	13,692
<b>Total Shareholders' Equity</b>	<b>17,278</b>	<b>16,186</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>\$57,048</b>	<b>\$43,706</b>

<sup>1</sup> Restated for two-for-one stock split effective May 21, 2004.

See accompanying Notes to Consolidated Financial Statements



## 210 • Specimen Financial Statements: The Procter &amp; Gamble Company

## Consolidated Statements of Shareholders' Equity

(Restated for two-for-one stock split effective May 21, 2004)

Dollars in millions/ Shares in thousands	Common Shares Outstanding	Common Stock	Preferred Stock	Additional Paid-In Capital	Reserve for ESOP Debt Retirement	Accumulated Other Comprehensive Income	Retained Earnings	Total	Total Comprehensive Income
<b>Balance June 30, 2001</b>	2,591,476	\$2,591	\$1,701	\$762	\$(1,375)	\$(2,120)	\$10,451	\$12,010	
Net earnings							4,352	4,352	\$4,352
Other comprehensive income:									
Financial statement translation						263		263	263
Net investment hedges, net of \$238 tax						(397)		(397)	(397)
Other, net of tax benefits						(106)		(106)	(106)
Total comprehensive income									\$4,112
Dividends to shareholders:									
Common							(1,971)	(1,971)	
Preferred, net of tax benefits							(124)	(124)	
Spin-off of Jif and Crisco							(150)	(150)	
Treasury purchases	(15,363)	(15)		25 <sup>1,2</sup>			(578)	(568)	
Employee plan issuances	16,646	17		344				361	
Preferred stock conversions	8,781	9	(67)	58				-	
ESOP debt guarantee reduction					36			36	
<b>Balance June 30, 2002</b>	2,601,540	2,602	1,634	1,189	(1,339)	(2,360)	11,980	13,706	
Net earnings							5,186	5,186	\$5,186
Other comprehensive income:									
Financial statement translation						804		804	804
Net investment hedges, net of \$251 tax						(418)		(418)	(418)
Other, net of tax benefits						(32)		(32)	(32)
Total comprehensive income									\$5,540
Dividends to shareholders:									
Common							(2,121)	(2,121)	
Preferred, net of tax benefits							(125)	(125)	
Treasury purchases	(28,276)	(28)		20 <sup>1,2</sup>			(1,228)	(1,236)	
Employee plan issuances	14,312	14		377				391	
Preferred stock conversions	6,819	6	(54)	48				-	
ESOP debt guarantee reduction					31			31	
<b>Balance June 30, 2003</b>	2,594,395	2,594	1,580	1,634	(1,308)	(2,006)	13,692	16,186	
Net earnings							6,481	6,481	\$6,481
Other comprehensive income:									
Financial statement translation						750		750	750
Net investment hedges, net of \$207 tax						(348)		(348)	(348)
Other, net of tax benefits						59		59	59
Total comprehensive income									\$6,942
Dividends to shareholders:									
Common							(2,408)	(2,408)	
Preferred, net of tax benefits							(131)	(131)	
Treasury purchases	(79,893)	(80)		33 <sup>2</sup>			(4,023)	(4,070)	
Employee plan issuances	22,678	23		711				734	
Preferred stock conversions	6,658	7	(54)	47				-	
ESOP debt guarantee reduction					25			25	
<b>Balance June 30, 2004</b>	2,543,838	\$2,544	\$1,526	\$2,425	\$(1,283)	\$(1,545)	\$13,611	\$17,278	

<sup>1</sup> Premium on equity put options totaled \$6 and \$18 for 2003 and 2002, respectively.<sup>2</sup> Includes impacts arising from stock split.

See accompanying Notes to Consolidated Financial Statements

## Notes to Consolidated Financial Statements

### Note 1 Summary of Significant Accounting Policies

#### Nature of Operations

The Procter & Gamble Company's (the Company) business is focused on providing consumer branded products of superior quality and value. The Company markets approximately 300 consumer products in more than 160 countries around the world. Our products are sold primarily through retail operations including mass merchandisers, grocery stores, membership club stores and drug stores.

#### Basis of Presentation

The Consolidated Financial Statements include The Procter & Gamble Company and its controlled subsidiaries. Intercompany transactions are eliminated in consolidation. Investments in certain companies over which the Company exerts significant influence, but does not control the financial and operating decisions, are accounted for as equity method investments.

#### Use of Estimates

Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying disclosures. These estimates are based on management's best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, consumer and trade promotion accruals, pensions, post-employment benefits, stock options, useful lives for depreciation and amortization, future cash flows associated with impairment testing for goodwill and long-lived assets, deferred tax assets, potential income tax assessments and contingencies. Actual results may ultimately differ from estimates, although management does not believe such changes would materially affect the financial statements in any individual year.

#### Revenue Recognition

Sales are recognized when revenue is realized or realizable and has been earned. Most revenue transactions represent sales of inventory, and the revenue recorded includes shipping and handling costs, which generally are included in the list price to the customer. The Company's policy is to recognize revenue when title to the product, ownership and risk of loss transfer to the customer, which generally is on the date of shipment. A provision for payment discounts and product return allowances is recorded as a reduction of sales in the same period that the revenue is recognized.

Trade promotions, consisting primarily of customer pricing allowances, merchandising funds and consumer coupons, are offered through various programs to customers and consumers. Sales are recorded net of trade promotion spending, which is recognized as incurred, generally at the time of the sale. Most of these arrangements have terms of approximately one year. Accruals for expected payouts under these programs are included as accrued marketing and promotion in the accrued and other current liabilities line in the Consolidated Balance Sheets.

#### Cost of Products Sold

Cost of products sold primarily comprises direct materials and supplies consumed in the manufacture of product, as well as manufacturing labor and direct overhead expense necessary to acquire and convert the purchased materials and supplies into finished product. Cost of products sold also includes the cost to distribute products to customers, inbound freight costs, internal transfer costs, warehousing costs and other shipping and handling activity. Shipping and handling costs invoiced to customers are included in net sales.

#### Selling, General and Administrative

Selling, general and administrative expense primarily includes marketing expenses, including the cost of media, advertising and related costs; selling expenses; research and development costs; administrative and other indirect overhead costs; and other miscellaneous operating items.

#### Other Non-Operating Income, Net

Other non-operating income, net primarily includes interest and investment income and gains and losses from divestitures.

#### Currency Translation

Financial statements of operating subsidiaries outside the United States of America (U.S.) generally are measured using the local currency as the functional currency. Adjustments to translate those statements into U.S. dollars are recorded in other comprehensive income (OCI). For subsidiaries operating in highly inflationary economies, the U.S. dollar is the functional currency. Remeasurement adjustments for financial statements in highly inflationary economies and other transactional exchange gains and losses are reflected in earnings.

#### Cash Flow Presentation

The Statement of Cash Flows is prepared using the indirect method, which reconciles net earnings to cash flow from operating activities. These adjustments include the removal of timing differences between the occurrence of operating receipts and payments and their recognition in net earnings. The adjustments also remove from operating activities cash flows arising from investing and financing activities, which are

## 212 • Specimen Financial Statements: The Procter & Gamble Company

presented separately from operating activities. Cash flows from foreign currency transactions and operations are translated at an average exchange rate for the period. Cash flows from hedging activities are included in the same category as the items being hedged. Cash flows from derivative instruments designated as net investment hedges are classified as financing activities. Cash flows from other derivative instruments used to manage interest, commodity or currency exposures are classified as operating activities. Cash paid for acquisitions is classified as investing activities.

### Cash Equivalents

Highly liquid investments with maturities of three months or less when purchased are considered cash equivalents and recorded at cost.

### Investments

Investment securities consist of readily-marketable debt and equity securities. These securities are reported at fair value. Unrealized gains or losses on securities classified as trading are charged to earnings. Unrealized gains or losses on securities classified as available for sale are recorded net of tax in OCI.

Other investments that are not controlled and over which the Company does not have the ability to exercise significant influence are accounted under the cost method.

### Inventory Valuation

Inventories are valued at cost, which is not in excess of current market prices. Product-related inventories are primarily maintained on the first-in, first-out method. Minor amounts of product inventories, including certain cosmetics and commodities are maintained on the last-in, first-out method. The cost of spare part inventories is maintained using the average cost method.

### Goodwill and Other Intangible Assets

The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed, principally on a straight-line basis over the estimated periods benefited. Goodwill and indefinite-lived intangibles are not amortized, but are evaluated annually for impairment. The Company evaluates a number of factors to determine whether an indefinite life is appropriate, including the competitive environment, market share, brand history, operating plan and the macroeconomic environment of the country in which the brand is sold. Due to the nature of the Company's business, there are a number of brand intangibles that have been determined to have

indefinite lives. If it is determined that a brand intangible does not have an indefinite life, the Company's policy is to amortize such assets over the expected useful life, which generally ranges from 5 to 20 years. Patents, technology and other intangibles with contractual terms are amortized over their respective contractual lives. Other non-contractual intangible assets with determinable lives are amortized over periods ranging from 5 to 20 years.

Where certain events or changes in operating conditions occur, lives on intangible assets with determinable lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate internal projections of expected future cash flows and operating plans.

### Property, Plant and Equipment

Property, plant and equipment are recorded at cost reduced by accumulated depreciation. Depreciation expense is recognized over the assets' estimated useful lives using the straight-line method. Machinery and equipment includes office furniture and equipment (15-year life), computer equipment and capitalized software (3 to 5-year lives) and manufacturing equipment (3 to 20-year lives). Buildings are depreciated over an estimated useful life of 40 years. Estimated useful lives are periodically reviewed and, where appropriate, changes are made prospectively. Where certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts.

### Fair Values of Financial Instruments

Certain financial instruments are required to be recorded at fair value. The estimated fair values of such financial instruments, including certain debt instruments, investment securities and derivatives, have been determined using market information and valuation methodologies, primarily discounted cash flow analysis. These estimates require considerable judgment in interpreting market data and changes in assumptions or estimation methods could significantly affect the fair value estimates. However, the Company does not believe any such changes would have a material impact on its financial condition or results of operations. Other financial instruments, including cash equivalents, other investments and short-term debt, are recorded at cost, which approximates fair value. The fair value of long-term debt is disclosed in Note 6.

Millions of dollars except per share amounts

## Specimen Financial Statements: The Procter &amp; Gamble Company • 213

**Stock-Based Compensation**

The Company has employee stock option plans, which are described more fully in Note 8. The Company accounts for its employee stock option plans under the intrinsic value recognition and measurement provisions of Accounting Principles Board (APB) Opinion No. 25, "Accounting for Stock Issued to Employees," and related interpretations. As stock options have been issued with exercise prices equal to the market value of the underlying shares on the grant date, no compensation expense has resulted.

Had compensation expense for the plans been determined based on the fair value of the options on the grant date, consistent with SFAS No. 123, "Accounting for Stock-Based Compensation," the Company's net earnings and earnings per common share would have been as follows:

	Years ended June 30		
	2004 <sup>1</sup>	2003	2002
<b>Net Earnings</b>			
As reported	\$6,481	\$5,186	\$4,352
Pro forma adjustments	(325)	(398)	(442)
<b>Pro forma</b>	<b>6,156</b>	<b>4,788</b>	<b>3,910</b>

**Net Earnings Per Common Share**

Basic			
As reported	\$2.46	\$1.95	\$1.63
Pro forma adjustments	(0.12)	(0.15)	(0.17)
<b>Pro forma</b>	<b>2.34</b>	<b>1.80</b>	<b>1.46</b>
Diluted			
As reported	2.32	1.85	1.54
Pro forma adjustments	(0.12)	(0.15)	(0.15)
<b>Pro forma</b>	<b>2.20</b>	<b>1.70</b>	<b>1.39</b>

<sup>1</sup> During the current year, the timing of the annual grant was moved from September to February resulting in lower expense, as the associated pro forma expense is amortized over the three-year vesting period.

**Stock Split**

In March 2004, the Company's Board of Directors approved a two-for-one stock split effective for common and preferred shareholders of record as of May 21, 2004. The financial statements, notes and other references to share and per share data have been restated to reflect the stock split for all periods presented.

**New Pronouncements and Reclassifications**

No new accounting pronouncements issued or effective during the fiscal year have had or are expected to have a material impact on the financial statements. Certain reclassifications of prior years' amounts have been made to conform to the current year presentation.

**Note 2 Restructuring Program**

In 1999, concurrent with a reorganization of its operations into product-based Global Business Units, the Company initiated a multi-year restructuring program. Costs included enrollment reductions, manufacturing consolidations and portfolio choices to scale back or discontinue under-performing businesses and initiatives. Total restructuring program charges were \$751 in 2003, including \$351 in separations related to approximately 5,000 people, \$190 in asset write-downs and \$87 in accelerated depreciation related to long-lived assets that were taken out of service prior to the end of their normal service period. Total restructuring program charges were \$958 in 2002, including \$393 in separations related to approximately 7,400 people, \$208 in asset write-downs and \$135 in accelerated depreciation.

At June 30, 2003, the program was substantially complete with a remaining reserve of \$335. Substantially all of this liability was settled through cash payments by the end of 2004.

The Company continues to undertake projects to maintain a competitive cost structure, including manufacturing streamlining and work force rationalization, as part of its normal operations.

**Note 3 Acquisitions and Spin-Off****Wella Acquisition**

On September 2, 2003, the Company acquired a controlling interest in Wella AG (Wella). Through a stock purchase agreement with the majority shareholders of Wella and a tender offer made on the remaining shares, the Company acquired a total of 81% of Wella's outstanding shares, including 99% of Wella's outstanding voting class shares. In June 2004, the Company and Wella entered into a Domination and Profit Transfer Agreement (the Domination Agreement) pursuant to which the Company is entitled to exercise full operating control and receive 100% of the future earnings of Wella. As consideration for the Domination Agreement, the Company will pay the holders of the remaining outstanding shares of Wella a guaranteed perpetual annual dividend payment. Alternatively, the remaining Wella shareholders may elect to tender their shares to the Company for an agreed price. The fair value of the total guaranteed annual dividend payments is \$1.11 billion, which approximates the cost if all remaining shares were tendered. Because the Domination Agreement transfers operational and economic control of the remaining outstanding shares to the Company, it has been accounted for as an acquisition of the remaining shares, with a liability recorded equal to the fair value of the guaranteed payments. Because of the tender feature, the liability is recorded as a current liability in the accrued and other liabilities

Millions of dollars except per share amounts

## 214 • Specimen Financial Statements: The Procter & Gamble Company

line of the Consolidated Balance Sheets. Payments made under the guaranteed annual dividend provisions will be allocated between interest expense and a reduction of the liability, as appropriate. The total purchase price for Wella, including acquisition costs, was \$6.27 billion based on exchange rates at the acquisition dates. It was funded with a combination of cash, debt and the liability recorded under the Domination Agreement

The acquisition of Wella, with over \$3 billion in annual net sales, gives the Company access to the professional hair care category plus greater scale and scope in hair care, hair colorants, cosmetics and fragrance products, while providing potential for significant synergies. The operating results of the Wella business are reported in the Company's Beauty Care business segment beginning September 2, 2003.

The following table provides pro forma results of operations for the years ended June 30, 2004, 2003 and 2002, as if Wella had been acquired as of the beginning of each fiscal year presented. The pro forma results include certain adjustments, including adjustments to convert Wella's historical financial information from International Accounting Standards (IAS) into U.S. GAAP, estimated interest impacts from funding of the acquisition and estimated amortization of definite-lived intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the integration of Wella. Accordingly, such amounts are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the dates indicated or that may result in the future.

Pro forma results	Years ended June 30		
	2004	2003	2002
<b>Net Sales</b>	<b>\$51,958</b>	\$46,751	\$43,070
<b>Net Earnings</b>	<b>6,402</b>	5,222	4,345
<b>Diluted Net Earnings per Common Share</b>	<b>\$2.29</b>	\$1.86	\$1.54

The Company is in the process of finalizing independent appraisals for certain assets to assist management in allocating the purchase price to the individual assets acquired and liabilities assumed. This may result in adjustments to the carrying values of Wella's recorded assets and liabilities, including the amount of any residual value allocated to goodwill. The Company is also completing its analysis of collaboration plans that may result in additional purchase price allocation adjustments. The preliminary allocation of the purchase price included in the current period balance sheet is based on the current best estimates of man-

agement and is subject to revision based on final determination of fair values and collaboration plans. The Company anticipates the valuations and other studies will be completed prior to the anniversary date of the acquisition. The preliminary allocation of the total purchase price of Wella resulted in the following condensed balance sheet of assets acquired and liabilities assumed.

Current assets	\$1,825
Property, plant and equipment	443
Goodwill	5,864
Intangible assets	1,709
Other non-current assets	225
<b>Total assets acquired</b>	<b>10,066</b>

Current liabilities	2,114
Non-current liabilities	1,679
<b>Total liabilities assumed</b>	<b>3,793</b>
<b>Net assets acquired</b>	<b>6,273</b>

The Wella acquisition resulted in \$5.86 billion in goodwill, all of which was allocated to the Beauty Care segment, and \$1.71 billion in total intangible assets acquired with \$1.15 billion allocated to trademarks with indefinite lives. The remaining \$556 of acquired intangibles have determinable useful lives and were assigned to trademarks of \$267, patents and technology of \$10, professional customer relationships of \$214 and license and other intangible assets of \$65. Total intangible assets acquired with determinable lives have a weighted-average life of 11 years (8 years for trademarks, 5 years for patents and technology, 15 years for professional customer relationships and 23 years for license and other intangible assets).

### China Venture

On June 18, 2004, the Company purchased the remaining 20% stake in its China venture from its partner, Hutchison Whampoa China Ltd. (Hutchison), giving the Company full ownership in its operations in China. The net purchase price was \$1.85 billion, which is the purchase price of \$2.00 billion net of minority interest and related obligations that were eliminated as a result of the transaction. The acquisition was funded by debt. The fair value of the incremental individual assets and liabilities acquired approximates current book value. Accordingly, the purchase price was recorded as goodwill, which was allocated to multiple business segments.

Millions of dollars except per share amounts

## Specimen Financial Statements: The Procter &amp; Gamble Company • 215

**Clairol Acquisition**

On November 16, 2001, the Company completed the acquisition of the Clairol business from The Bristol-Myers Squibb Company for approximately \$5.03 billion in cash, financed primarily with debt. The operating results of the Clairol business are reported in the Company's Beauty Care segment beginning November 16, 2001.

The following table provides pro forma results of operations for the year ended June 30, 2002 as if Clairol had been acquired as of the beginning of the fiscal year. Pro forma information for 2004 and 2003 is not presented as the results of Clairol are included with those of the Company for the entire year. The pro forma results include adjustments for estimated interest expense on acquisition funding and amortization of definite-lived intangible assets. However, pro forma results do not include any anticipated cost savings or other effects of the integration of Clairol. Accordingly, such amounts are not necessarily indicative of the results that would have occurred if the acquisition had closed on the dates indicated or that may result in the future.

	Year ended June 30
Pro forma results	2002
<b>Net Sales</b>	\$40,780
<b>Net Earnings</b>	4,406
<b>Diluted Net Earnings per Common Share</b>	\$1.56

**Jif and Crisco Spin-off**

On May 31, 2002, the Jif peanut butter and Crisco shortening brands were spun off to the Company's shareholders and subsequently merged into The J.M. Smucker Company (Smucker). The Company's shareholders received one new common Smucker share for every 50 shares held in the Company, totaling 26 million shares, or approximately \$900 in market value. This transaction was not included in the results of operations, since a spin-off to the Company's shareholders is recorded at net book value, or \$150, in a manner similar to dividends.

Other minor business purchases and intangible asset acquisitions totaled \$384, \$61 and \$446 in 2004, 2003 and 2002, respectively.

**Note 4 Goodwill and Intangible Assets**

The change in net carrying amount of goodwill for the years ended June 30, 2004 and 2003 was allocated by reportable business segment as follows:

	2004	2003
<b>Fabric and Home Care</b> , beginning of year	<b>\$460</b>	\$451
Acquisitions	148	-
Translation and other	6	9
<b>End of year</b>	<b>614</b>	460
<b>Baby and Family Care</b> , beginning of year	<b>884</b>	830
Acquisitions	19	-
Translation and other	38	54
<b>End of year</b>	<b>941</b>	884
<b>Beauty Care</b> , beginning of year	<b>6,600</b>	6,542
Acquisitions	7,277	-
Translation and other	580	58
<b>End of year</b>	<b>14,457</b>	6,600
<b>Health Care</b> , beginning of year	<b>2,908</b>	2,866
Acquisitions	386	-
Translation and other	21	42
<b>End of year</b>	<b>3,315</b>	2,908
<b>Snacks and Beverages</b> , beginning of year	<b>280</b>	277
Translation and other	3	3
<b>End of year</b>	<b>283</b>	280
<b>Goodwill, Net</b> , beginning of year	<b>11,132</b>	10,966
Acquisitions	7,830	-
Translation and other	648	166
<b>End of year</b>	<b>19,610</b>	11,132

For the year ended June 30, 2004, goodwill increased primarily due to the acquisition of Wella and the purchase of the remaining stake in the China venture.

Identifiable intangible assets as of June 30, 2004 and 2003 were comprised of:

	June 30, 2004		June 30, 2003	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
<b>Intangible Assets with Determinable Lives</b>				
Trademarks	\$1,012	\$155	\$499	\$85
Patents and technology	518	250	492	204
Other	554	165	316	140
	<b>2,084</b>	<b>570</b>	1,307	429
<b>Trademarks with Indefinite Lives</b>				
	<b>2,945</b>	<b>169</b>	1,666	169
	<b>5,029</b>	<b>739</b>	2,973	598

Millions of dollars except per share amounts

## 216 • Specimen Financial Statements: The Procter & Gamble Company

The amortization of intangible assets for the years ended June 30, 2004, 2003 and 2002 was \$165, \$100 and \$97, respectively. Estimated amortization expense over the next five years is as follows: 2005 - \$171; 2006 - \$169; 2007 - \$119; 2008 - \$106; and 2009 - \$104. Such estimates do not reflect the impact of future foreign exchange rate changes.

### Note 5 Supplemental Financial Information

Selected components of current and non-current liabilities were as follows:

	June 30	
	2004	2003
<b>Accrued and Other Current Liabilities</b>		
Marketing and promotion	\$1,876	\$1,802
Liability under Wella		
Domination Agreement	1,106	-
Compensation expenses	1,049	804
Other	3,658	2,906
	<b>7,689</b>	<b>5,512</b>
<b>Other Non-Current Liabilities</b>		
Pension benefits	\$1,798	\$1,301
Other postretirement benefits	142	181
Other	868	809
	<b>2,808</b>	<b>2,291</b>

### Selected Operating Expenses

Research and development costs are charged to earnings as incurred and were \$1,802 in 2004, \$1,665 in 2003 and \$1,601 in 2002. Advertising costs are charged to earnings as incurred and were \$5,504 in 2004, \$4,373 in 2003 and \$3,773 in 2002. Both of these are components of selling, general and administrative expense.

### Note 6 Short-Term and Long-Term Debt

	June 30	
	2004	2003
<b>Short-Term Debt</b>		
USD commercial paper	\$6,059	\$717
Non-USD commercial paper	149	147
Current portion of long-term debt	1,518	1,093
Other	561	215
	<b>8,287</b>	<b>2,172</b>

The weighted average short-term interest rates were 1.5% and 3.6% as of June 30, 2004 and 2003, respectively. The rate decrease reflected an increase in commercial paper within short-term debt.

	June 30	
	2004	2003
<b>Long-Term Debt</b>		
6.60% USD note due December, 2004	\$1,000	\$1,000
4.00% USD note due April, 2005	400	400
5.75% EUR note due September, 2005	1,827	1,725
1.50% JPY note due December, 2005	503	459
3.50% CHF note due February, 2006	240	222
5.40% EUR note due August, 2006	365	-
4.75% USD note due June, 2007	1,000	1,000
6.13% USD note due May, 2008	500	500
4.30% USD note due August, 2008	500	500
3.50% USD note due December, 2008	650	-
6.88% USD note due September, 2009	1,000	1,000
2.00% JPY note due June, 2010	458	417
9.36% ESOP debentures due 2007-2021 <sup>1</sup>	1,000	1,000
4.85% USD note due December, 2015	700	-
8.00% USD note due September, 2024	200	200
6.45% USD note due January, 2026	300	300
6.25% GBP note due January, 2030	906	827
5.25% GBP note due January, 2033	363	331
5.50% USD note due February, 2034	500	-
Debt assumed by acquiring non-cash capital leases	252	146
All other long-term debt	1,408	2,541
Current portion of long-term debt	(1,518)	(1,093)
	<b>12,554</b>	<b>11,475</b>

<sup>1</sup> Debt issued by the ESOP is guaranteed by the Company and must be recorded as debt of the Company as discussed in Note 9.

Long-term weighted average interest rates were 4.0% and 3.7% as of June 30, 2004 and 2003, respectively, and included the effects of related interest rate swaps discussed in Note 7.

The fair value of the long-term debt was \$13,168 and \$12,396 at June 30, 2004 and 2003, respectively. Long-term debt maturities during the next five fiscal years are as follows: 2005 - \$1,518; 2006 - \$2,625; 2007 - \$1,433; 2008 - \$972; and 2009 - \$1,150. The Company has no material obligations that are secured.

Millions of dollars except per share amounts

*Specimen Financial Statements: The Procter & Gamble Company • 217***Note 7 Risk Management Activities**

As a multinational company with diverse product offerings, the Company is exposed to market risks, such as changes in interest rates, currency exchange rates and commodity pricing. To manage the volatility related to these exposures, the Company evaluates exposures on a consolidated basis to take advantage of logical exposure netting. For the remaining exposures, the Company enters into various derivative transactions. Such derivative transactions, which are executed in accordance with the Company's policies in areas such as counterparty exposure and hedging practices, are accounted for under SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities," as amended and interpreted. The Company does not hold or issue derivative financial instruments for speculative trading purposes.

At inception, the Company formally designates and documents the financial instrument as a hedge of a specific underlying exposure. The Company formally assesses, both at inception and at least quarterly on an ongoing basis, whether the financial instruments used in hedging transactions are effective at offsetting changes in either the fair value or cash flows of the related underlying exposure. Fluctuations in the derivative value generally are offset by changes in the fair value or cash flows of the exposures being hedged. This offset is driven by the high degree of effectiveness between the exposure being hedged and the hedging instrument. Any ineffective portion of an instrument's change in fair value is immediately recognized in earnings.

**Credit Risk**

The Company has established strict counterparty credit guidelines and normally enters into transactions with investment grade financial institutions. Counterparty exposures are monitored daily and downgrades in credit rating are reviewed on a timely basis. Credit risk arising from the inability of a counterparty to meet the terms of the Company's financial instrument contracts generally is limited to the amounts, if any, by which the counterparty's obligations exceed the obligations of the Company. The Company does not expect to incur material credit losses on its risk management or other financial instruments.

**Interest Rate Management**

The Company's policy is to manage interest cost using a mixture of fixed-rate and variable-rate debt. To manage this risk in a cost efficient manner, the Company enters into interest rate swaps in which the Company agrees to exchange, at specified intervals, the difference between fixed and variable interest amounts calculated by reference to an agreed-upon notional principal amount.

Interest rate swaps that meet specific conditions under SFAS No. 133 are accounted for as fair value hedges. Changes in the fair value of both the hedging instruments and the underlying debt obligations are immediately recognized in earnings as equal and offsetting gains and losses in the interest expense component of the income statement. The fair value of the Company's interest rate swap agreements was a net asset of \$45 and \$322 at June 30, 2004 and 2003, respectively. All existing fair value hedges are 100% effective. As a result, there is no impact to earnings due to hedge ineffectiveness.

**Foreign Currency Management**

The Company manufactures and sells its products in a number of countries throughout the world and, as a result, is exposed to movements in foreign currency exchange rates. The purpose of the Company's foreign currency hedging program is to reduce the risk caused by short-term changes in exchange rates.

The Company primarily utilizes forward exchange contracts and purchased options with maturities of less than 18 months and currency swaps with maturities up to 5 years. These instruments are intended to offset the effect of exchange rate fluctuations on forecasted sales, inventory purchases, intercompany royalties and intercompany loans denominated in foreign currencies and are therefore accounted for as cash flow hedges. The fair value of these instruments at June 30, 2004 and June 30, 2003 was \$47 and \$27 in assets and \$140 and \$92 in liabilities, respectively. The effective portion of the changes in fair value for these instruments are reported in OCI and reclassified into earnings in the same financial statement line item and in the same period or periods during which the hedged transactions affect earnings. The ineffective portion, which is not material for any year presented, is immediately recognized in earnings.

Certain instruments used by the Company for foreign exchange risk do not meet the requirements for hedge accounting treatment. In these cases, the change in value of the instruments is designed to offset the foreign currency impact of intercompany financing transactions, income from international operations and other balance sheet revaluations. The fair value of these instruments at June 30, 2004 and 2003 was \$71 and \$113 in assets and \$26 and \$26 in liabilities, respectively. The gain or loss on these instruments is immediately recognized in earnings. The net impact of such instruments, included in selling, general and administrative expense, was \$80, \$264 and \$50 of gains in 2004, 2003 and 2002, respectively, which substantially offset foreign currency transaction losses of the items being hedged.

Millions of dollars except per share amounts



## 218 • Specimen Financial Statements: The Procter & Gamble Company

### Net Investment Hedging

The Company hedges certain net investment positions in major currencies. To accomplish this, the Company borrows directly in foreign currency and designates a portion of foreign currency debt as a hedge of net investments in foreign subsidiaries. In addition, certain foreign currency swaps are designated as hedges of the Company's related foreign net investments. Under SFAS No. 133, changes in the fair value of these instruments are immediately recognized in OCI, to offset the change in the value of the net investment being hedged. Currency effects of these hedges reflected in OCI were a \$348 and \$418 after-tax loss in 2004 and 2003, respectively. Accumulated net balances were a \$586 after-tax loss in 2004 and a \$238 after-tax loss in 2003.

### Commodity Price Management

Raw materials used by the Company are subject to price volatility caused by weather, supply conditions, political and economic variables and other unpredictable factors. To manage the volatility related to certain anticipated inventory purchases, the Company uses futures and options with maturities generally less than one year and swap contracts with maturities up to five years. These market instruments are designated as cash flow hedges under SFAS No. 133. Accordingly, the mark-to-market gain or loss on qualifying hedges is reported in OCI and reclassified into cost of products sold in the same period or periods during which the hedged transaction affects earnings. Qualifying cash flow hedges currently recorded in OCI are not considered material. The mark-to-market gain or loss on non-qualifying, excluded and ineffective portions of hedges is immediately recognized in cost of products sold. Commodity hedging activity was not material to the Company's financial statements for any of the years presented.

## Note 8 Earnings Per Share and Stock Options

### Net Earnings Per Common Share

Net earnings less preferred dividends (net of related tax benefits) are divided by the weighted average number of common shares outstanding during the year to calculate basic net earnings per common share. Diluted net earnings per common share are calculated to give effect to stock options and assuming conversion of preferred stock (see Note 9).

Net earnings and common share balances used to calculate basic and diluted net earnings per share were as follows:

	Years ended June 30		
	2004	2003	2002
<b>Net Earnings</b>	<b>\$6,481</b>	\$5,186	\$4,352
Preferred dividends, net of tax benefit	(131)	(125)	(124)
<b>Net earnings available to common shareholders</b>	<b>6,350</b>	5,061	4,228
Preferred dividends, net of tax benefit	131	125	124
Preferred dividend impact on funding of ESOP	(4)	(9)	(12)
<b>Diluted net earnings</b>	<b>6,477</b>	5,177	4,340

	Years ended June 30		
	2004	2003	2002
Shares in millions			
Basic weighted average common shares outstanding	2,580.1	2,593.2	2,594.8
Effect of dilutive securities			
Conversion of preferred shares <sup>1</sup>	164.0	170.2	177.6
Exercise of stock options <sup>2</sup>	46.0	39.2	37.5
<b>Diluted weighted average common shares outstanding</b>	<b>2,790.1</b>	2,802.6	2,809.9

<sup>1</sup> Despite being included currently in diluted net earnings per common share, the actual conversion to common stock occurs pursuant to the repayment of the ESOP debt through 2021.

<sup>2</sup> Approximately 38 million in 2004, 66 million in 2003 and 72 million in 2002 of the Company's outstanding stock options were not included in the diluted net earnings per share calculation because to do so would have been antidilutive (i.e., the exercise price exceeded market value).

### Stock-Based Compensation

The Company has a primary stock-based compensation plan under which stock options are granted annually to key managers and directors with exercise prices equal to the market price of the underlying shares on the date of grant. Grants were made under plans approved by shareholders in 1992, 2001 and 2003. Grants issued since September 2002 are vested after three years and have a ten-year life. Grants issued from July 1998 through August 2002 are vested after three years and have a fifteen-year life, while grants issued prior to July 1998 are vested after one year and have a ten-year life. The Company also makes other minor grants to employees, for which vesting terms and option lives are not substantially different.

Millions of dollars except per share amounts

## Specimen Financial Statements: The Procter &amp; Gamble Company • 219

Had the provision of SFAS No. 123 expensing been applied, the Company's net earnings and earnings per common share would have been impacted as summarized in the discussion of the Company's stock-based compensation accounting policy in Note 1. In calculating the impact for options granted, the Company has estimated the fair value of each grant using the Black-Scholes option-pricing model. Assumptions are evaluated and revised, as necessary, to reflect market conditions and experience. The following assumptions were used:

Options Granted	Years ended June 30		
	2004	2003	2002
Interest rate	3.8%	3.9%	5.4%
Dividend yield	1.8%	1.8%	2.2%
Expected volatility	20%	20%	20%
Expected life in years	8	8	12

The following table summarizes stock option activity during 2004, 2003 and 2002:

Options in Thousands	June 30		
	2004	2003	2002
Outstanding, beginning of year	259,598	240,326	208,392
Granted	40,866	35,759	50,080
Jif and Crisco spin-off adjustment	-	-	1,622
Exercised	(22,307)	(13,904)	(16,297)
Canceled	(1,864)	(2,583)	(3,471)
<b>Outstanding, end of year</b>	<b>276,293</b>	<b>259,598</b>	<b>240,326</b>
Exercisable	151,828	118,202	92,664
Available for grant	165,399	203,593	229,071
Average price			
Outstanding, beginning of year	\$35.75	\$33.34	\$31.82
Granted	51.06	45.68	35.09
Exercised	24.88	19.35	14.53
Outstanding, end of year	38.85	35.75	33.34
Exercisable, end of year	35.39	35.44	28.50
Weighted average fair value of options granted during the year	12.50	10.99	10.57

Millions of dollars except per share amounts

Stock options outstanding at June 30, 2004 were in the following exercise price ranges:

Range of Prices	Outstanding Options		
	Number Outstanding (Thousands)	Weighted Avg. Exercise Price	Weighted Avg. Remaining Contractual Life in Years
\$16.43 to 30.11	36,863	\$24.07	2.6
31.01 to 34.84	95,260	32.72	11.5
35.10 to 46.24	82,825	43.70	6.9
48.73 to 52.98	61,345	50.69	9.9

Stock options exercisable at June 30, 2004 were in the following exercise price ranges:

Range of Prices	Exercisable Options	
	Number Exercisable (Thousands)	Weighted Average Exercise Price
\$16.43 to 30.11	36,863	\$24.07
31.01 to 34.84	48,426	31.06
35.10 to 46.24	43,624	42.36
48.73 to 52.98	22,915	49.49

The Company repurchases common shares to mitigate the dilutive impact of options. Beyond that, the Company may make additional discretionary purchases based on cash availability, market trends and other factors.

In limited cases, the Company also issues stock appreciation rights, generally in countries where stock options are not permitted by local governments. The obligations and associated compensation expense are adjusted for changes in intrinsic value. The impact of these adjustments is not material.

#### Note 9 Postretirement Benefits and Employee Stock Ownership Plan

The Company offers various postretirement benefits to its employees.

##### Defined Contribution Retirement Plans

The most prevalent employee benefit plans offered are defined contribution plans, which cover substantially all employees in the U.S., as well as employees in certain other countries. These plans are fully funded.

## 220 • Specimen Financial Statements: The Procter & Gamble Company

Under the defined contribution plans, the Company generally makes contributions to participants based on individual base salaries and years of service. In the U.S., the contribution is set annually. Historically, the Company has contributed approximately 15% of total participants' annual wages and salaries.

The Company maintains The Procter & Gamble Profit Sharing Trust (Trust) and Employee Stock Ownership Plan (ESOP) to provide a portion of the funding for the U.S. defined contribution plan, as well as other retiree benefits. Operating details of the ESOP are provided at the end of this Note. The fair value of the ESOP Series A shares reduces the Company's cash contribution required to fund the U.S. defined contribution plan. Defined contribution expense, which approximates the Company's cash contribution to the plan that is funded in the subsequent year, was \$274, \$286 and \$279 in 2004, 2003 and 2002, respectively.

### Defined Benefit Retirement Plans and Other Retiree Benefits

Certain other employees, primarily outside the U.S., are covered by local defined benefit pension plans as well as other retiree benefit plans.

The Company also provides certain other retiree benefits, primarily health care and life insurance, for substantially all U.S. employees who become eligible for these benefits when they meet minimum age and service requirements. Generally, the health care plans require cost sharing with retirees and pay a stated percentage of expenses, reduced by deductibles and other coverages. These benefits primarily are funded by ESOP Series B shares, as well as certain other assets contributed by the Company.

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 was signed into law on December 8, 2003. This Act introduces a Medicare prescription-drug benefit beginning in 2006 as well as a federal subsidy to sponsors of retiree health care plans that provide a benefit at least "actuarially equivalent" to the Medicare benefit. Management has concluded that the Company's plans are at least "actuarially equivalent" to the Medicare benefit and, accordingly, has included the federal subsidy from the Act in the normal year-end measurement process for other retiree benefit plans. The impact is a reduction to the benefit obligation of \$195 as of June 30, 2004. The impact to net periodic pension cost and to benefits paid in future years is not expected to be material.

**Obligation and Funded Status.** The Company uses a June 30 measurement date for its defined benefit retirement plans and other retiree benefit plans. The following provides a reconciliation of benefit obligations, plan assets and funded status of these plans:

	Years ended June 30			
	Pension Benefits		Other Retiree Benefits	
	2004	2003	2004	2003
<b>Change in benefit obligation</b>				
Benefit obligation at				
beginning of year <sup>1</sup>	\$3,543	\$2,970	\$2,914	\$2,135
Service cost	157	124	89	62
Interest cost	204	173	172	150
Participants'				
contributions	14	7	31	27
Amendments	50	(33)	(258)	(2)
Actuarial loss (gain)	5	138	(460)	645
Acquisitions	590	42	7	-
Curtailments				
and settlements	(39)	(29)	(8)	-
Special termination				
benefits	12	1	41	7
Currency translation	288	305	5	13
Benefit payments	(208)	(155)	(133)	(123)
<b>Benefit obligation</b>				
<b>at end of year<sup>1</sup></b>	<b>4,616</b>	<b>3,543</b>	<b>2,400</b>	<b>2,914</b>
<b>Change in plan assets</b>				
Fair value of plan				
assets at				
beginning of year	\$1,558	\$1,332	\$2,277	\$2,347
Actual return on				
plan assets	194	(36)	651	1
Acquisitions	185	1	-	-
Employer				
contributions	412	337	18	25
Participants'				
contributions	14	7	31	27
Settlements	(21)	(27)	-	-
Currency translation	129	99	(1)	-
Benefit payments	(208)	(155)	(133)	(123)
<b>Fair value of plan assets</b>				
<b>at end of year</b>	<b>2,263</b>	<b>1,558</b>	<b>2,843</b>	<b>2,277</b>
<b>Funded status</b>	<b>(2,353)</b>	<b>(1,985)</b>	<b>443</b>	<b>(637)</b>

<sup>1</sup> For the pension benefit plans, the benefit obligation is the projected benefit obligation. For other retiree benefit plans, the benefit obligation is the accumulated postretirement benefit obligation.

Millions of dollars except per share amounts

## Specimen Financial Statements: The Procter &amp; Gamble Company • 221

	Years ended June 30			
	Pension Benefits		Other Retiree Benefits	
	2004	2003	2004	2003
<b>Calculation of net amount recognized</b>				
Funded status at end of year	<b>\$(2,353)</b>	\$(1,985)	<b>\$443</b>	\$(637)
Unrecognized net actuarial loss (gain)	<b>902</b>	930	<b>(344)</b>	435
Unrecognized transition amount	<b>12</b>	13	-	-
Unrecognized prior service cost	<b>38</b>	(9)	<b>(259)</b>	(2)
<b>Net amount recognized</b>	<b>(1,401)</b>	(1,051)	<b>(160)</b>	(204)

	Years ended June 30			
	Pension Benefits		Other Retiree Benefits	
	2004	2003	2004	2003
<b>Classification of net amount recognized</b>				
Prepaid benefit cost	<b>\$253</b>	\$173	<b>\$1</b>	\$2
Accrued benefit cost	<b>(1,872)</b>	(1,407)	<b>(161)</b>	(206)
Intangible asset	<b>75</b>	31	-	-
Accumulated other comprehensive income	<b>143</b>	152	-	-
<b>Net amount recognized</b>	<b>(1,401)</b>	(1,051)	<b>(160)</b>	(204)

The underfunding of pension benefits is primarily a function of the different funding incentives that exist outside of the U.S. In certain countries where the Company has major operations, there are no legal requirements or financial incentives provided to companies to pre-fund pension obligations. In these instances, benefit payments are typically paid directly from the Company's cash as they become due, rather than through the creation of a separate pension fund.

The accumulated benefit obligation for all defined benefit retirement plans was \$3,822 and \$2,850 at June 30, 2004 and June 30, 2003, respectively. Plans with accumulated benefit obligations in excess of plan assets and plans with projected benefit obligations in excess of plan assets as of June 30, consist of the following:

	Years ended June 30			
	Accumulated Benefit Obligation Exceeds Fair Value of Plan Assets		Projected Benefit Obligation Exceeds Fair Value of Plan Assets	
	2004	2003	2004	2003
Projected benefit obligation	<b>\$2,809</b>	\$2,945	<b>\$4,059</b>	\$3,179
Accumulated benefit obligation	<b>2,396</b>	2,310	<b>3,320</b>	2,492
Fair value of plan assets	<b>638</b>	979	<b>1,676</b>	1,186

**Net Periodic Benefit Cost.** Components of the net periodic benefit cost were as follows:

	Years ended June 30					
	Pension Benefits			Other Retiree Benefits		
	2004	2003	2002	2004	2003	2002
Service cost	<b>\$157</b>	\$124	\$114	<b>\$89</b>	\$62	\$49
Interest cost	<b>204</b>	173	153	<b>172</b>	150	116
Expected return on plan assets	<b>(153)</b>	(127)	(133)	<b>(329)</b>	(333)	(320)
Amortization of deferred amounts	<b>3</b>	4	7	<b>(1)</b>	(1)	(1)
Curtailment and settlement loss (gain)	-	5	1	-	-	(1)
Recognized net actuarial loss (gain)	<b>28</b>	13	9	<b>1</b>	(27)	(64)
<b>Gross benefit cost</b>	<b>239</b>	192	151	<b>(68)</b>	(149)	(221)
Dividends on ESOP preferred stock	-	-	-	<b>(73)</b>	(74)	(76)
<b>Net periodic benefit cost</b>	<b>239</b>	192	151	<b>(141)</b>	(223)	(297)

Millions of dollars except per share amounts

## 222 • Specimen Financial Statements: The Procter & Gamble Company

**Assumptions.** The Company determines its actuarial assumptions on an annual basis. These assumptions are weighted to reflect each country that may have an impact on the cost of providing retirement benefits. The weighted-average assumptions for the defined benefit and other retiree benefit calculations, as well as assumed health care cost trend rates, for the years ended June 30, are as follows:

Actuarial assumptions	Years ended June 30			
	Pension Benefits		Other Retiree Benefits	
	2004	2003	2004	2003
<b>Assumptions used to determine benefit obligations<sup>1</sup></b>				
Discount rate	5.2%	5.1%	6.1%	5.8%
Rate of compensation increase	3.1%	3.1%	-	-
<b>Assumptions used to determine net periodic pension cost<sup>2</sup></b>				
Discount rate	5.1%	5.6%	5.8%	7.0%
Expected return on plan assets	7.4%	7.7%	9.5%	9.5%
Rate of compensation increase	3.0%	3.5%	-	-
<b>Assumed health care cost trend rates</b>				
Health care cost trend rates assumed for next year <sup>3</sup>	-	-	9.7%	11.4%
Rate that the health care cost trend rate is assumed to decline to (ultimate trend rate)	-	-	5.1%	5.0%
Year that the rate reaches the ultimate trend rate	-	-	2010	2010

<sup>1</sup> Determined as of end of year.

<sup>2</sup> Determined as of beginning of year.

<sup>3</sup> Rate is applied to current plan costs net of Medicare; estimated initial rate for "gross eligible charges" (charges inclusive of Medicare) is 7.7% for 2004 and 8.8% for 2003.

Several factors are considered in developing the estimate for the long-term expected rate of return on plan assets. For the defined benefit plans, these include historical rates of return of broad equity and bond indices and projected long-term rates of return from pension investment consultants. The expected long-term rates of return for plan assets are 8%-9% for equities and 5%-6% bonds. The rate of return on other retiree benefit plan assets, comprised primarily of Company stock, is based on the long-term projected return of 9.5% and reflects the historical pattern of favorable returns on the Company's stock relative to broader market indices (e.g., S&P 500).

Assumed health care cost trend rates could have a significant effect on the amounts reported for the other retiree benefit plans. A one-percentage point change in assumed health care cost trend rates would have the following effects:

	One-Percentage Point Increase	One-Percentage Point Decrease
Effect on total service and interest cost components	\$51	\$(46)
Effect on postretirement benefit obligation	323	(268)

**Plan Assets.** The Company's target asset allocation for the year ending June 30, 2005 and actual asset allocation by asset category as of June 30, 2004, and 2003, are as follows:

Asset Category	Target Allocation	
	Pension Benefits	Other Retiree Benefits
	2005	2005
Equity securities <sup>1</sup>	64%	99%
Debt securities	32%	1%
Real estate	4%	-%
<b>Total</b>	100%	100%

Asset Category	Plan Asset Allocation at June 30			
	Pension Benefits		Other Retiree Benefits	
	2004	2003	2004	2003
Equity securities <sup>1</sup>	64%	62%	99%	99%
Debt securities	32%	35%	1%	1%
Real estate	4%	3%	-%	-%
<b>Total</b>	100%	100%	100%	100%

<sup>1</sup> Equity securities for other retiree plan assets include Company stock, net of Series B ESOP debt (see Note 6), of \$2,744 and \$2,182, as of June 30, 2004 and 2003, respectively.

Millions of dollars except per share amounts

*Specimen Financial Statements: The Procter & Gamble Company* • 223

The Company's investment objective for defined benefit plan assets is to meet the plans' benefit obligations, while minimizing the potential for future required Company plan contributions. The investment strategies focus on asset class diversification, liquidity to meet benefit payments and an appropriate balance of long-term investment return and risk. Target ranges for asset allocations are determined by matching the actuarial projections of the plans' future liabilities and benefit payments with expected long-term rates of return on the assets, taking into account investment return volatility and correlations across asset classes. Plan assets are diversified across several investment managers and are generally invested in liquid funds that are selected to track broad market equity and bond indices. Investment risk is carefully controlled with plan assets rebalanced to target allocations on a periodic basis and continual monitoring of investment managers performance relative to the investment guidelines established with each investment manager.

**Cash Flows.** Management's best estimate of its cash requirements for the defined benefit plans and other retiree benefit plans for the year ending June 30, 2005 is \$237 and \$20, respectively. For the defined benefit plans, this is comprised of expected benefit payments of \$71, which are paid directly to participants of unfunded plans from employer assets, as well as expected contributions to funded plans of \$166. For other retiree benefit plans, this is comprised of expected contributions that will be used directly for benefit payments. Expected contributions are dependent on many variables, including the variability of the market value of the assets as compared to the obligation and other market or regulatory conditions. In addition, the Company takes into consideration its business investment opportunities and resulting cash requirements. Accordingly, actual funding may differ greatly from current estimates.

Total benefit payments expected to be paid to participants, which include payments funded from the Company's assets, as discussed above, as well as payments paid from the plans are as follows:

	Years ended June 30	
	Pension Benefits	Other Retiree Benefits
<b>Expected benefit payments</b>		
2005	\$191	\$144
2006	177	152
2007	193	166
2008	207	176
2009	207	185
2010 – 2014	1,180	1,058

Millions of dollars except per share amounts

#### Employee Stock Ownership Plan

The Company maintains the ESOP to provide funding for certain employee benefits discussed in the preceding paragraphs.

The ESOP borrowed \$1.00 billion in 1989 and the proceeds were used to purchase Series A ESOP Convertible Class A Preferred Stock to fund a portion of the defined contribution retirement plan in the U.S. Principal and interest requirements were paid by the Trust from dividends on the preferred shares and from advances from the Company. The final payment for the original borrowing of \$1.00 billion was made in 2004 and the remaining debt of the ESOP consists of amounts owed to the Company. Each share is convertible at the option of the holder into one share of the Company's common stock. The dividend for the current year was \$0.93 per share. The liquidation value is \$6.82 per share.

In 1991, the ESOP borrowed an additional \$1.00 billion. The proceeds were used to purchase Series B ESOP Convertible Class A Preferred Stock to fund a portion of retiree health care benefits. These shares are considered plan assets, net of the associated debt, of the Other Retiree Benefits plan discussed above. Debt service requirements are funded by preferred stock dividends and cash contributions from the Company. Each share is convertible at the option of the holder into one share of the Company's common stock. The dividend for the current year was \$1.02 per share. The liquidation value is \$12.96 per share.

As permitted by Statement of Position (SOP) 93-6, "Employers Accounting for Employee Stock Ownership Plans," the Company has elected, where applicable, to continue its practices, which are based on SOP 76-3, "Accounting Practices for Certain Employee Stock Ownership Plans." ESOP debt, which is guaranteed by the Company, is recorded as debt (see Note 6). Preferred shares issued to the ESOP are offset by the reserve for ESOP debt retirement in the Consolidated Balance Sheets and the Consolidated Statements of Shareholders' Equity. Interest incurred on the ESOP debt is recorded as interest expense. Dividends on all preferred shares, net of related tax benefits, are charged to retained earnings.

## 224 • Specimen Financial Statements: The Procter & Gamble Company

As required by SOP 76-3, the preferred shares of the ESOP are allocated based on debt service requirements, net of advances made by the Company to the Trust. The number of preferred shares outstanding at June 30, was as follows:

Shares in Thousands	June 30		
	2004	2003	2002
Allocated	<b>62,511</b>	64,492	66,191
Unallocated	<b>28,296</b>	31,534	35,374
<b>Total Series A</b>	<b>90,807</b>	96,026	101,565
Allocated	<b>21,399</b>	20,648	19,738
Unallocated	<b>48,528</b>	50,718	52,908
<b>Total Series B</b>	<b>69,927</b>	71,366	72,646

For purposes of calculating diluted net earnings per common share, the preferred shares held by the ESOP are considered converted from inception. Diluted net earnings are calculated assuming that all preferred shares are converted to common, and therefore are adjusted to reflect the incremental ESOP funding that would be required due to the difference in dividend rate between preferred and common shares (see Note 8).

### Note 10 Income Taxes

Under SFAS No. 109, "Accounting for Income Taxes," income taxes are recognized for the amount of taxes payable for the current year and for the impact of deferred tax liabilities and assets, which represent future tax consequences of events that have been recognized differently in the financial statements than for tax purposes. Deferred tax assets and liabilities are established using the enacted statutory tax rates and are adjusted for changes in such rates in the period of change. Earnings before income taxes consisted of the following:

	Years ended June 30		
	2004	2003	2002
United States	<b>\$6,023</b>	\$4,920	\$4,411
International	<b>3,327</b>	2,610	1,972
	<b>9,350</b>	7,530	6,383

The income tax provision consisted of the following:

	Years ended June 30		
	2004	2003	2002
<b>Current Tax Expense</b>			
U.S. Federal	<b>\$1,508</b>	\$1,595	\$975
International	<b>830</b>	588	551
U.S. State and Local	<b>116</b>	98	116
	<b>2,454</b>	2,281	1,642
<b>Deferred Tax Expense</b>			
U.S. Federal	<b>348</b>	125	571
International and other	<b>67</b>	(62)	(182)
	<b>415</b>	63	389
	<b>2,869</b>	2,344	2,031

The Company's effective income tax rate was 30.7%, 31.1% and 31.8% in 2004, 2003 and 2002, respectively, compared to the U.S. statutory rate of 35.0%. The country mix impacts of foreign operations reduced the Company's effective tax rate to a larger degree in 2004 than the previous fiscal years: 4.1% in 2004, 3.8% in 2003 and 3.1% in 2002. The Company's higher effective tax rate in 2002 also reflected the impact of restructuring costs. Taxes impacted shareholders' equity with credits of \$351 and \$361 for the years ended June 30, 2004 and 2003, respectively. These primarily relate to the tax effects of net investment hedges and tax benefits from the exercise of stock options.

The Company has undistributed earnings of foreign subsidiaries of \$16.75 billion at June 30, 2004, for which deferred taxes have not been provided. Such earnings are considered indefinitely invested in the foreign subsidiaries. If such earnings were repatriated, additional tax expense may result, although the calculation of such additional taxes is not practicable.

Millions of dollars except per share amounts

*Specimen Financial Statements: The Procter & Gamble Company* • 225

Deferred income tax assets and liabilities were comprised of the following:

	June 30	
	2004	2003
<b>Deferred Tax Assets</b>		
Unrealized loss on financial instruments	\$381	\$287
Loss and other carryforwards	365	311
Advance payments	226	182
Other postretirement benefits	95	93
Other	1,169	820
Valuation allowances	(342)	(158)
	<b>1,894</b>	<b>1,535</b>
<b>Deferred Tax Liabilities</b>		
Fixed assets	(1,350)	(1,175)
Goodwill and other intangible assets	(1,281)	(410)
Other	(352)	(287)
	<b>(2,983)</b>	<b>(1,872)</b>

Net operating loss carryforwards were \$1,398 and \$1,222 at June 30, 2004 and June 30, 2003, respectively. If unused, \$299 will expire between 2005 and 2014. The remainder, totaling \$1,099 at June 30, 2004, may be carried forward indefinitely.

#### Note 11 Commitments and Contingencies

##### Guarantees

In conjunction with certain transactions, primarily divestitures, the Company may provide routine indemnifications (e.g., retention of previously existing environmental, tax and employee liabilities) whose terms range in duration and often are not explicitly defined. Generally, the maximum obligation under such indemnifications is not explicitly stated and, as a result, the overall amount of these obligations cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically the Company has not made significant payments for these indemnifications. The Company believes that if it were to incur a loss in any of these matters, the loss would not have a material effect on the Company's financial condition or results of operations.

In certain situations, the Company guarantees loans for suppliers and customers. The total amount of guarantees issued under such arrangements is not material.

##### Off-Balance Sheet Arrangements

The Company does not have off-balance sheet financing arrangements, including variable interest entities, under FASB Interpretation No. 46, "Consolidation of Variable Interest Entities," that have a material impact on the financial statements.

##### Purchase Commitments

The Company has purchase commitments for materials, supplies, services and property, plant and equipment as part of the normal course of business. Due to the proprietary nature of many of the Company's materials and processes, certain supply contracts contain penalty provisions for early termination. The Company does not expect potential payments under these provisions to materially affect results of operations or its financial condition in any individual year.

##### Operating Leases

The Company leases certain property and equipment for varying periods under operating leases. Future minimum rental commitments under noncancellable operating leases are as follows: 2005 - \$186; 2006 - \$150; 2007 - \$134; 2008 - \$99; 2009 - \$86; and \$265 thereafter.

##### Litigation

The Company is subject to various lawsuits and claims with respect to matters such as governmental regulations, income taxes and other actions arising out of the normal course of business. The Company is also subject to contingencies pursuant to environmental laws and regulations that in the future may require the Company to take action to correct the effects on the environment of prior manufacturing and waste disposal practices. Accrued environmental liabilities for remediation and closure costs were \$36 and \$34 at June 30, 2004 and 2003, respectively. Current year expenditures were not material.

While considerable uncertainty exists, in the opinion of management and Company counsel, the ultimate liabilities resulting from such lawsuits and claims will not materially affect the Company's financial condition.

Millions of dollars except per share amounts



## 226 • Specimen Financial Statements: The Procter & Gamble Company

### Note 12 Segment Information

The Company is organized into five product-based Global Business Units. The segments, which are generally determined by the product type and end-point user benefits offered, manufacture and market products as follows:

- Fabric and Home Care includes laundry detergents, dish care, fabric enhancers and surface cleaners.
- Beauty Care includes retail and professional hair care, skin care, feminine care, cosmetics, fine fragrances and personal cleansing.
- Baby and Family Care includes diapers, baby wipes, bath tissue and kitchen towels.
- Health Care includes oral care, personal health care, pharmaceuticals and pet health and nutrition.
- Snacks and Beverages includes coffee, snacks, commercial services and juice. In August 2004, the Company divested the juice business.

Effective July 1, 2004, the Company realigned its businesses and associated management responsibilities to three business units: Beauty Care; Health, Baby and Family Care; and Household Care, which will include the current Fabric and Home Care business as well as the Snacks and Beverages business.

The accounting policies of the operating segments are generally the same as those described in Note 1, Summary of Significant Accounting Policies. Differences from these policies and U.S. GAAP primarily reflect: income taxes, which are reflected in the business segments using estimated local statutory rates; the recording of fixed assets at historical exchange rates in certain high inflation economies; and the treatment of unconsolidated investees. Unconsolidated investees are managed as integral parts of the Company's business units for management and segment reporting purposes. Accordingly, these partially owned operations are reflected as consolidated subsidiaries in segment results, with 100% recognition of the individual income statement line items through before-tax earnings, while after-tax earnings are adjusted to reflect only the Company's ownership percentage. Entries to eliminate the individual revenues and expenses, adjusting the method of accounting to the equity method as required by U.S. GAAP, are included in Corporate.

Corporate includes certain operating and non-operating activities that are not reflected in the operating results used internally to measure and evaluate the operating segments, as well as eliminations to adjust management reporting principles to U.S. GAAP. Operating activities in Corporate include the results of incidental businesses managed at the corporate level along with the elimination of individual revenues and expenses generated by companies over which the Company exerts significant influence, but does not control. Operating elements also comprise intangible asset amortization, certain employee benefit costs and other general corporate items. The non-operating elements include financing and investing activities. In addition, Corporate includes the historical results of certain divested businesses of the former Food and Beverage segment. Corporate assets primarily include cash, investment securities, goodwill and other non-current intangible assets.

The Company had net sales in the U.S. of \$23,688, \$21,853 and \$21,198 for the years ended June 30, 2004, 2003 and 2002, respectively. Assets in the U.S. totaled \$23,687 and \$23,424 as of June 30, 2004 and 2003, respectively.

The Company's largest customer, Wal-Mart Stores, Inc. and its affiliates, accounted for 17%, 18% and 17% of consolidated net sales in 2004, 2003 and 2002, respectively. These sales occurred primarily in the U.S.

Millions of dollars except per share amounts

## Specimen Financial Statements: The Procter &amp; Gamble Company • 227

		Fabric and Home Care	Beauty Care	Baby and Family Care	Health Care	Snacks and Beverages	Corporate	Total
<b>Net Sales</b>	<b>2004</b>	<b>\$13,868</b>	<b>\$17,122</b>	<b>\$10,718</b>	<b>\$6,991</b>	<b>\$3,482</b>	<b>\$(774)</b>	<b>\$51,407</b>
	2003	12,560	12,221	9,933	5,796	3,238	(371)	43,377
	2002	11,618	10,723	9,233	4,979	3,249	436	40,238
<b>Before-Tax Earnings</b>	<b>2004</b>	<b>3,287</b>	<b>3,662</b>	<b>1,623</b>	<b>1,448</b>	<b>557</b>	<b>(1,227)</b>	<b>9,350</b>
	2003	3,080	2,899	1,448	1,034	460	(1,391)	7,530
	2002	2,728	2,354	1,272	795	476	(1,242)	6,383
<b>Net Earnings</b>	<b>2004</b>	<b>2,203</b>	<b>2,422</b>	<b>996</b>	<b>962</b>	<b>363</b>	<b>(465)</b>	<b>6,481</b>
	2003	2,059	1,984	882	706	306	(751)	5,186
	2002	1,831	1,610	738	521	303	(651)	4,352
<b>Depreciation and Amortization</b>	<b>2004</b>	<b>331</b>	<b>393</b>	<b>550</b>	<b>153</b>	<b>119</b>	<b>187</b>	<b>1,733</b>
	2003	332	345	558	156	125	187	1,703
	2002	326	339	503	163	121	241	1,693
<b>Total Assets</b>	<b>2004</b>	<b>5,512</b>	<b>7,869</b>	<b>7,229</b>	<b>2,639</b>	<b>1,831</b>	<b>31,968</b>	<b>57,048</b>
	2003	5,174	5,389	6,974	2,642	2,040	21,487	43,706
<b>Capital Expenditures</b>	<b>2004</b>	<b>538</b>	<b>433</b>	<b>714</b>	<b>164</b>	<b>134</b>	<b>41</b>	<b>2,024</b>
	2003	357	343	548	144	125	(35)	1,482
	2002	368	354	702	158	125	(28)	1,679

## Note 13 Quarterly Results (Unaudited)

		Quarters Ended				Total Year
		Sept 30	Dec 31	Mar 31	Jun 30	
<b>Net Sales</b>	<b>2003–2004</b>	<b>\$12,195</b>	<b>\$13,221</b>	<b>\$13,029</b>	<b>\$12,962</b>	<b>\$51,407</b>
	2002–2003	10,796	11,005	10,656	10,920	43,377
<b>Operating Income</b>	<b>2003–2004</b>	<b>2,643</b>	<b>2,742</b>	<b>2,303</b>	<b>2,139</b>	<b>9,827</b>
	2002–2003	2,179	2,248	1,957	1,469	7,853
<b>Net Earnings</b>	<b>2003–2004</b>	<b>1,761</b>	<b>1,818</b>	<b>1,528</b>	<b>1,374</b>	<b>6,481</b>
	2002–2003	1,464	1,494	1,273	955	5,186
<b>Diluted Net Earnings Per Common Share<sup>1</sup></b>	<b>2003–2004</b>	<b>\$0.63</b>	<b>\$0.65</b>	<b>\$0.55</b>	<b>\$0.50</b>	<b>\$2.32</b>
	2002–2003	0.52	0.53	0.46	0.34	1.85

<sup>1</sup> Restated for two-for-one stock split effective May 21, 2004.

Millions of dollars except per share amounts

## 228 • Specimen Financial Statements: The Procter &amp; Gamble Company

## Financial Summary (Unaudited)

	2004	2003	2002	2001	2000	1999	1998	1997	1996
Net Sales	\$51,407	\$43,377	\$40,238	\$ 39,244	\$39,951	\$38,125	\$37,154	\$35,764	\$35,284
Operating Income	9,827	7,853	6,678	4,736	5,954	6,253	6,055	5,488	4,815
Net Earnings	6,481	5,186	4,352	2,922	3,542	3,763	3,780	3,415	3,046
Net Earnings Margin	12.6%	12.0%	10.8%	7.4%	8.9%	9.9%	10.2%	9.5%	8.6%
Basic Net Earnings Per									
Common Share <sup>1</sup>	\$2.46	\$1.95	\$1.63	\$1.08	\$1.30	\$1.38	\$1.37	\$1.22	\$1.07
Diluted Net Earnings									
Per Common Share <sup>1</sup>	2.32	1.85	1.54	1.03	1.23	1.29	1.28	1.14	1.00
Dividends Per									
Common Share <sup>1</sup>	0.93	0.82	0.76	0.70	0.64	0.57	0.51	0.45	0.40
Restructuring									
Program Charges <sup>2</sup>	\$-	\$751	\$958	\$1,850	\$814	\$481	\$-	\$-	\$-
Research and									
Development Expense	1,802	1,665	1,601	1,769	1,899	1,726	1,546	1,469	1,399
Advertising Expense	5,504	4,373	3,773	3,612	3,793	3,639	3,801	3,574	3,374
Total Assets	57,048	43,706	40,776	34,387	34,366	32,192	31,042	27,598	27,762
Capital Expenditures	2,024	1,482	1,679	2,486	3,018	2,828	2,559	2,129	2,179
Long-Term Debt	12,554	11,475	11,201	9,792	9,012	6,265	5,774	4,159	4,678
Shareholders' Equity	17,278	16,186	13,706	12,010	12,287	12,058	12,236	12,046	11,722

<sup>1</sup> Restated for two-for-one stock split effective May 21, 2004.

<sup>2</sup> Restructuring program charges, on an after-tax basis, totaled \$538, \$706, \$1,475, \$688 and \$385 for 2003, 2002, 2001, 2000 and 1999 respectively.